Filing Flows › Lyell Immunopharma (LYEL) › Q2 2026 › vs Q2 2025
Lyell Immunopharma (LYEL) Q2 2026 vs Q2 2025 (year over year)
Lyell Immunopharma's revenue fell $4K (-50%) from $8K in Q2 2025 to $4K in Q2 2026.
Lyell Immunopharma, Q2 2026: revenue $4K (-50% year over year), net loss $44.8M, operating cash flow −$33.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $4K | $8K | −$4K | -50% |
| Other income, net | $2.6M | $4.5M | −$1.9M | -42% |
| Net loss | $44.8M | $42.7M | $2.1M | +5% |
| Costs & expenses | $47.3M | $47.1M | $193K | +0.4% |
| Operating costs | $47.3M | $47.1M | $193K | +0.4% |
| Operating cash sources | $44.8M | $42.7M | $2.1M | +5% |
| Depreciation & amortization | $2.2M | $3.1M | −$913K | -29% |
| Share-based compensation | $4.5M | $5.0M | −$472K | -9% |
| Working capital & other | $4.1M | $87K | $4.0M | 47× |
| Cash used in operations | $33.9M | $34.5M | −$536K | -2% |
| Net loss absorbed | $44.8M | $42.7M | $2.1M | +5% |
Questions
How much did Lyell Immunopharma's revenue grow year over year in Q2 2026?
Lyell Immunopharma's revenue fell $4K (-50%) from $8K in Q2 2025 to $4K in Q2 2026.